Experimental Drug DNL343 Fails to Slow ALS Progression in Randomized Trial
A randomized clinical trial in JAMA Network Open found that 200 mg per day of DNL343, an eIF2B activator, did ...
A randomized clinical trial in JAMA Network Open found that 200 mg per day of DNL343, an eIF2B activator, did ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine